JP7130639B2 - 5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用 - Google Patents
5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用 Download PDFInfo
- Publication number
- JP7130639B2 JP7130639B2 JP2019523008A JP2019523008A JP7130639B2 JP 7130639 B2 JP7130639 B2 JP 7130639B2 JP 2019523008 A JP2019523008 A JP 2019523008A JP 2019523008 A JP2019523008 A JP 2019523008A JP 7130639 B2 JP7130639 B2 JP 7130639B2
- Authority
- JP
- Japan
- Prior art keywords
- mir
- halouracil
- modified
- cancer
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Description
本出願は、2017年2月28日出願の米国仮特許出願第62/464,491号;2016年11月15日出願の米国仮特許出願第62/422,298号及び2016年11月1日出願の米国仮特許出願第62/415,740号の優先権を主張し、その全体の内容が参照により本明細書に組み込まれる。
本開示は、National Institutes of Healthによって授与された許可番号HL127522及びCA197098下の政府支援によりなされた。政府は、本開示において一定の権利を有する。
2017年10月30日に作成され、United States Patent and Trademark OfficeにEFS-Webを介して提出された、R8859_PCT_SequenceListing.txtと命名された、7KBのASCIIテキストファイル中の配列表は、参照により本明細書に組み込まれる。
用語「マイクロRNA」又は「miRNA」又は「miR」は、互換的に使用され、メッセンジャーRNA分子(mRNA)、DNA又はタンパク質との相互作用により遺伝子の発現を制御する能力があるスモール非コードリボース核酸(RNA)分子を指す。典型的には、マイクロRNAは、約19~25ヌクレオチド(塩基)の核酸配列から構成され、哺乳動物細胞において見出される。
別の態様において、本開示は、本明細書に記載される修飾核酸組成物の製剤を対象とする。例えば、本核酸組成物は、薬学的用途のため製剤化されうる。特定の実施形態において、製剤は、本明細書に記載される核酸組成物及び薬学的に許容される担体を含有する医薬組成物である。他の実施形態において、本開示の製剤は、修飾miR-129核酸、修飾miR-15a核酸、修飾miR-140核酸、修飾miR-192核酸、修飾miR-502、修飾miR-506核酸又はその組合せ及び薬学的に許容される担体を含む。より具体的には、以下のヌクレオチド配列に示される修飾マイクロRNA核酸は、薬学的適用及び使用のため製剤化されうる;CUFUFUFUFUFGCGGUFCUFGGGCUFUFGC[配列番号4]、CUUUUUGCGGUFCUFGGGCUFUFGC[配列番号5]、UFAGCAGCACAUFAAUFGGUFUFUFGUFG[配列番号6]、UAGCAGCACAUFAAUFGGUFUFUFGUFG[配列番号7]、CAGUFGGUUUUACCCUFAUGGUFAG[配列番号9]、CUFGACCUFAUFGAAUFUFGACAGCC[配列番号1]、AUFCCUFUFGCUAUFCUFGGGUFGCUFA[配列番号13]、及びUFAUFUFCAGGAAGGUFGUFUFACUFUFAA[配列番号15]。
上述したとおり、本開示の修飾マイクロRNA核酸組成物及びその製剤は、天然マイクロRNA及び/又は公知のがん治療(化学療法)、例えば、5-FUによって示される活性と比較した場合に、予想外の及び特別な抗がん活性を示す。したがって、本開示の別の態様は、哺乳動物に本開示の有効量の1つ以上の修飾マイクロRNA核酸組成物又はその製剤を投与する工程による、哺乳動物におけるがんを治療するための方法を提供する。
材料及び方法。
修飾miR-129:5-FU修飾miR-129分子を、自動化オリゴヌクレオチド合成プロセスによって合成し、HPLCによって精製した。2つの鎖をアニールして、成熟修飾5-FU-miR-129を作った。より具体的には、「2'-ACE RNA合成」と呼ばれるプロセスを使用した。2'-ACE RNA合成は、シリルエーテルを用いて、2'-ヒドロキシにおける酸不安定性オルトエステル保護基(2'-ACE)を組み合わせて5'-ヒドロキシル基を保護する、保護基スキームに基づく。この保護基の組合せは、次に標準的なホスホラミダイト固相合成技術で使用される。例えば、それらの各々の全体の内容が本明細書に明示的に組み込まれる、S.A. Scaringe、F.E. Wincott、and M.H. Caruthers、J. Am. Chem. Soc.、120 (45)、11820~11821 (1998);国際PCT出願WO/1996/041809;M.D. Matteucci、M.H. Caruthers、J. Am. Chem. Soc.、103、3185~3191 (1981);S.L. Beaucage、M.H. Caruthers、Tetrahedron Lett. 22、1859~1862 (1981)を参照されたい。
本開示の修飾マイクロRNAは抗がん活性を有する。
図3、図8B、図12A-B、図13A-B及び図14A-Dに示されるように、修飾miRNA(修飾miR:129、15a、192(215)、140、502、及び506)は、非修飾miRNA前駆体よりも、結腸がん、膵がん及び肺がん細胞増殖の阻害においてより有効である。加えて、修飾miRNAは、トランスフェクション試薬なしでがん細胞に送達することができる(データ示さず)。とりわけ、結果は、いくつかの異なる結腸直腸がん細胞株、膵臓がん細胞株、及び肺がん細胞株を越え、がん細胞増殖が、対照マイクロRNAで処置したがん細胞と比較した場合に、有意に阻害されることを示している。
修飾miR-129核酸は抗がん活性を有する。
以下の実験では、5-FUを、miR-129に組み込んだ。1つの実験では、miR-129中の全てのU塩基を、図1Aに提供される構造に示されるように、5-FUで置き換えた、ここで、「UF」は、5-フルオロウラシル又は他の5-ハロウラシルを表す。別の実験では、miR-129のシード領域を除く、全てのU塩基を、図1Bに提供される構造に示されるように、5-FUで置き換えた。
修飾miR-15a及びその抗がん活性。
例示的な修飾miR-15a組成物は、抗がん活性を有する。図1C及び図1Dに示されるように、miR-15a核酸配列の全てのウラシル塩基(図1C)又は非シード領域中のウラシル塩基のみ(図1D)が、5-ハロウラシル(すなわち、5-フルオロウラシル)で置き換えられた、例示的な修飾miR-15aを、上記に示されるように合成した。
Claims (15)
- 少なくとも1つのウラシル核酸を含む修飾マイクロRNAヌクレオチドを含む2本鎖核酸組成物であって、前記少なくとも1つのウラシル核酸の1つ以上が、5-ハロウラシルであり、前記修飾マイクロRNAヌクレオチドが、配列番号1に示される配列を有するmiR-129又は配列番号2に示される配列を有するmiR-15aからなる群から選択されるマイクロRNAヌクレオチドの配列と相補的な配列を有するB細胞リンパ腫2(BCL2)ヌクレオチドの一部と結合し、
前記修飾マイクロRNAヌクレオチドが、CU F U F U F U F U F GCGGU F CU F GGGCU F U F GC[配列番号4]及びU F AGCAGCACAU F AAU F GGU F U F U F GU F G[配列番号6]からなる群から選択されるマイクロRNAヌクレオチドを含み、ここで、U F は、5-ハロウラシルである、
2本鎖核酸組成物。 - 前記5-ハロウラシルが、5-フルオロウラシルである、請求項1に記載の組成物。
- 前記ヌクレオチド中の前記ウラシル核酸の少なくとも2つが、5-ハロウラシルである、請求項1に記載の組成物。
- 前記ヌクレオチド中の前記ウラシル核酸の少なくとも3つが、5-ハロウラシルである、請求項3に記載の組成物。
- 前記ヌクレオチド中の前記ウラシル核酸の少なくとも4つが、5-ハロウラシルである、請求項4に記載の組成物。
- 前記ヌクレオチド中の前記ウラシル核酸の少なくとも5つが、5-ハロウラシルである、請求項5に記載の組成物。
- 前記ヌクレオチド中のウラシル核酸の少なくとも6つが、5-ハロウラシルである、請求項6に記載の組成物。
- 前記ヌクレオチド中のウラシル核酸の全てが、5-ハロウラシルである、請求項1に記載の組成物。
- 請求項1に記載の2本鎖核酸組成物及び薬学的に許容される担体を含む医薬組成物。
- 前記5-ハロウラシルが、5-フルオロウラシルである、請求項9に記載の医薬組成物。
- 対象におけるがんを治療するための医薬の調製のための請求項1に記載の2本鎖核酸組成物の使用であって、前記対象が、がんを有するか又はがんを発症する素因を有すると診断されており、前記がんの進行が、阻害される、使用。
- 哺乳動物が、ヒトである、請求項11に記載の使用。
- 前記対象が、結腸直腸、膵臓又は肺がんからなる群から選択されるがんを有する、請求項12に記載の使用。
- 前記対象が、結腸直腸がんを有する、請求項13に記載の使用。
- 前記2本鎖核酸組成物が、CUFUFUFUFUFGCGGUFCUFGGGCUFUFGC[配列番号4]及びUFAGCAGCACAUFAAUFGGUFUFUFGUFG[配列番号6]からなる群から選択され、前記5-ハロウラシルが、5-フルオロウラシルである、請求項11~14のいずれか一項に記載の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022133279A JP2022173194A (ja) | 2016-11-01 | 2022-08-24 | 5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662415740P | 2016-11-01 | 2016-11-01 | |
US62/415,740 | 2016-11-01 | ||
US201662422298P | 2016-11-15 | 2016-11-15 | |
US62/422,298 | 2016-11-15 | ||
US201762464491P | 2017-02-28 | 2017-02-28 | |
US62/464,491 | 2017-02-28 | ||
PCT/US2017/059011 WO2018085198A1 (en) | 2016-11-01 | 2017-10-30 | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022133279A Division JP2022173194A (ja) | 2016-11-01 | 2022-08-24 | 5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019533697A JP2019533697A (ja) | 2019-11-21 |
JP7130639B2 true JP7130639B2 (ja) | 2022-09-05 |
Family
ID=62077036
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019523008A Active JP7130639B2 (ja) | 2016-11-01 | 2017-10-30 | 5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用 |
JP2022133279A Pending JP2022173194A (ja) | 2016-11-01 | 2022-08-24 | 5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022133279A Pending JP2022173194A (ja) | 2016-11-01 | 2022-08-24 | 5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用 |
Country Status (12)
Country | Link |
---|---|
US (2) | US11584932B2 (ja) |
EP (2) | EP3534912A4 (ja) |
JP (2) | JP7130639B2 (ja) |
KR (2) | KR102502248B1 (ja) |
CN (2) | CN110290794A (ja) |
AU (2) | AU2017353907B2 (ja) |
BR (1) | BR112019008810A2 (ja) |
CA (1) | CA3042401A1 (ja) |
IL (1) | IL282836A (ja) |
MX (1) | MX2019005101A (ja) |
SG (1) | SG11202104571RA (ja) |
WO (2) | WO2018085198A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110527728A (zh) * | 2013-08-08 | 2019-12-03 | 纽约州州立大学研究基金会 | 作为子宫颈癌和存活期的生物标记物的角蛋白 |
US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
US10941403B2 (en) | 2018-04-02 | 2021-03-09 | Oregon Health & Science University | Microrna inhibitors as anti-cancer therapeutics |
US20220145304A1 (en) * | 2019-03-14 | 2022-05-12 | The Research Foundation For The State University Of New York | Modified micrornas and their use in the treatment of cancer |
MX2022011515A (es) * | 2020-03-18 | 2022-10-07 | Univ New York State Res Found | Composiciones de arn modificado de interferencia corta y su uso en el tratamiento del cancer. |
WO2021262919A2 (en) * | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010504349A (ja) | 2006-09-19 | 2010-02-12 | アシュラジェン インコーポレイテッド | 治療的介入の標的としてmiR−143によって調節される遺伝子および経路 |
JP2012532123A (ja) | 2009-06-29 | 2012-12-13 | アプタバイオ セラピュティックス インコーポレイテッド | 治療効能のある変形核酸及びグアノシンを含有するオリゴヌクレオチド変形体 |
US20130109628A1 (en) | 2010-07-15 | 2013-05-02 | Emory University | Microrna compositions and methods related thereto |
JP2013166766A (ja) | 2005-09-12 | 2013-08-29 | Ohio State Univ Research Foundation | Bcl2関連癌の診断及び療法のための組成物及び方法 |
WO2014100252A1 (en) | 2012-12-18 | 2014-06-26 | University Of Washington Through Its Center For Commercialization | Methods and compositions to modulate rna processing |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
CA2937159C (en) * | 2001-09-28 | 2017-11-28 | Thomas Tuschl | Microrna molecules |
US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US20050261217A1 (en) | 2004-05-18 | 2005-11-24 | Isis Pharmaceuticals Inc. | Modulation of pumilio 1 expression |
US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
US20070259349A1 (en) | 2006-05-04 | 2007-11-08 | Itzhak Bentwich | Bladder cancer-related nucleic acids |
US7592441B2 (en) | 2004-10-04 | 2009-09-22 | Rosetta Genomics Ltd | Liver cancer-related nucleic acids |
US7825229B2 (en) | 2005-03-25 | 2010-11-02 | Rosetta Genomics Ltd. | Lung cancer-related nucleic acids |
CA2850323A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
JP2008539731A (ja) | 2005-05-02 | 2008-11-20 | コールド スプリング ハーバー ラボラトリー | 癌の診断及び治療のための組成物及び方法 |
CA2610702A1 (en) | 2005-06-03 | 2006-12-07 | Michael Zenon Michael | Targeting cells with altered microrna expression |
US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
CN103866017B (zh) | 2005-08-01 | 2016-05-25 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
WO2007081720A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
AU2007205257B2 (en) | 2006-01-05 | 2013-07-25 | The Ohio State University Research Foundation | MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors |
EP2487253B1 (en) | 2006-01-05 | 2015-06-24 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
WO2007103808A2 (en) | 2006-03-02 | 2007-09-13 | The Ohio State University | Microrna expression profile associated with pancreatic cancer |
EP1996731A2 (en) | 2006-03-20 | 2008-12-03 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
EA201100813A1 (ru) | 2006-04-03 | 2012-06-29 | Сантарис Фарма А/С | Фармацевтическая композиция |
US20080076674A1 (en) | 2006-07-06 | 2008-03-27 | Thomas Litman | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer |
ES2447850T3 (es) | 2006-07-13 | 2014-03-13 | The Ohio State University Research Foundation | Métodos y composiciones basados en micro-ARN para el pronóstico y tratamiento de enfermedades relacionadas con el colon |
US8466117B2 (en) | 2006-07-28 | 2013-06-18 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
JP2010504350A (ja) | 2006-09-19 | 2010-02-12 | アシュラジェン インコーポレイテッド | 治療的介入の標的としての、miR−200によって調節される遺伝子および経路 |
WO2008046911A2 (en) | 2006-10-20 | 2008-04-24 | Exiqon A/S | Novel human micrornas associated with cancer |
US8188255B2 (en) | 2006-10-20 | 2012-05-29 | Exiqon A/S | Human microRNAs associated with cancer |
US20090137504A1 (en) | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
EP2113567B1 (en) | 2006-12-21 | 2019-04-03 | QIAGEN GmbH | MicroRNA target site blocking oligos and uses thereof |
EP2124967A4 (en) | 2007-01-26 | 2011-01-05 | Rosetta Genomics Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF HEMATOPOIETIC MALIGNOMES |
WO2008095096A2 (en) | 2007-01-31 | 2008-08-07 | Immune Disease Institute | Let-7 microrna and mimetics thereof as therapeutics for cancer |
US9006206B2 (en) | 2007-02-27 | 2015-04-14 | Rosetta Genomics Ltd. | Composition and methods for modulating cell proliferation and cell death |
WO2008137862A2 (en) | 2007-05-03 | 2008-11-13 | Rosetta Inpharmatics Llc | Methods of using mir34 as a biomarker for tp53 functional status |
CN101802227B (zh) * | 2007-07-18 | 2014-12-10 | 科罗拉多大学董事会法人团体 | 非衰竭与衰竭的人心脏中微小rna的差异表达 |
EP3138926A3 (en) | 2007-09-06 | 2017-04-05 | The Ohio State University Research Foundation | Microrna signatures in human ovarian cancer |
BRPI0816852A2 (pt) | 2007-09-14 | 2017-06-06 | Univ Ohio State Res Found | método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer. |
US8361714B2 (en) * | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
US20090136957A1 (en) | 2007-09-15 | 2009-05-28 | Irena Ivanovska | Methods and compositions for regulating cell cycle progression via the miR-106B family |
US20100285471A1 (en) | 2007-10-11 | 2010-11-11 | The Ohio State University Research Foundation | Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas |
AU2008318778B2 (en) | 2007-10-29 | 2014-10-02 | Regulus Therapeutics Inc. | Targeting microRNAs for the treatment of liver cancer |
US20110009469A1 (en) | 2007-12-05 | 2011-01-13 | The Johns Hopkins University | Compositions and methods of treating neoplasia |
JP2011517283A (ja) | 2008-02-28 | 2011-06-02 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 前立腺関連障害の予後診断及び治療のためのマイクロrnaに基づく方法及び組成物 |
US8252760B2 (en) | 2008-03-24 | 2012-08-28 | New York University | Compositions and methods for diagnosing and treating melanoma |
WO2009154835A2 (en) | 2008-03-26 | 2009-12-23 | Asuragen, Inc. | Compositions and methods related to mir-16 and therapy of prostate cancer |
US20100113284A1 (en) | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
US20090258928A1 (en) | 2008-04-08 | 2009-10-15 | Asuragen, Inc. | Methods and compositions for diagnosing and modulating human papillomavirus (hpv) |
US20110166200A1 (en) | 2008-04-24 | 2011-07-07 | Zhan Zhang | Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer |
ATE550024T1 (de) | 2008-05-30 | 2012-04-15 | Univ Yale | Gezielte oligonucleotid-zusammensetzungen zur modifizierung der genexpression |
WO2009147658A2 (en) | 2008-06-02 | 2009-12-10 | New York University | Compositions and methods for diagnosis, prognosis and treatment of mesothelioma |
WO2009149318A2 (en) * | 2008-06-05 | 2009-12-10 | Research Foundation Of State University Of New York | Mirnas as therapeutic targets in cancer |
US9540695B2 (en) | 2008-06-17 | 2017-01-10 | Rosetta Genomics Ltd. | Compositions and methods for prognosis of ovarian cancer |
EP2310507A4 (en) | 2008-07-08 | 2013-03-20 | David Gladstone Inst | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS |
US20110118337A1 (en) | 2008-07-10 | 2011-05-19 | Merck Sharp & Dohme Corp. | Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer |
WO2010023658A2 (en) | 2008-08-28 | 2010-03-04 | Rosetta Genomics Ltd. | Compositions and methods for the treatment of glioblastoma |
ES2727549T3 (es) | 2008-10-03 | 2019-10-17 | Curna Inc | Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1 |
WO2010065630A2 (en) | 2008-12-03 | 2010-06-10 | The Johns Hopkins University | Compositions and methods for treating hepatic neoplasia |
JP5971948B2 (ja) | 2008-12-04 | 2016-08-17 | クルナ・インコーポレーテッド | Vegfに対する天然アンチセンス転写物の抑制による血管内皮増殖因子(vegf)関連疾患の治療 |
CA2745811C (en) | 2008-12-04 | 2021-07-13 | Joseph Collard | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
ES2760912T3 (es) | 2008-12-04 | 2020-05-18 | Curna Inc | Tratamiento de enfermedades relacionadas con la Sirtuina 1 (SIRT1) por inhibición del transcrito antisentido natural de la Sirtuina 1 |
AU2009322907B2 (en) | 2008-12-05 | 2016-05-05 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer |
US20100311815A1 (en) | 2009-02-23 | 2010-12-09 | The Regents Of The University Of Michigan | Mir-101 cancer markers |
WO2010099342A2 (en) * | 2009-02-25 | 2010-09-02 | Cepheid | Methods of detecting lung cancer |
EP2403946A4 (en) | 2009-03-04 | 2012-11-14 | TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1 | |
WO2010104796A2 (en) | 2009-03-09 | 2010-09-16 | The J. David Gladstone Institutes | Methods of modulating smooth muscle cell proliferation and differentiation |
US20120087992A1 (en) * | 2009-03-20 | 2012-04-12 | Jingfang Ju | miRNAS AS THERAPEUTIC TARGETS IN CANCER |
US8852940B2 (en) * | 2009-04-01 | 2014-10-07 | The Regents Of The University Of California | Embryonic stem cell specific microRNAs promote induced pluripotency |
KR101758667B1 (ko) * | 2009-04-29 | 2017-07-18 | 아카데미쉬 메디쉬 센트륨 | 심부전 또는 심부전 위험성을 방지, 예방 및/또는 측정하기 위한 수단 및 방법 |
NO2424987T3 (ja) | 2009-05-01 | 2018-04-14 | ||
ES2609655T3 (es) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP |
WO2011014980A1 (en) | 2009-08-07 | 2011-02-10 | Capitalbio Corporation | Methods and compositions diagnosing cervical cancer and cervical dysplasia, guidding subsequent treatment, determining prognosis, and improving patient survival |
US8822144B2 (en) | 2009-08-19 | 2014-09-02 | Rosetta Genomics Ltd. | Compositions and methods for prognosis and treatment of prostate cancer |
WO2011024157A1 (en) | 2009-08-23 | 2011-03-03 | Rosetta Genomics Ltd. | Nucleic acid sequences related to cancer |
WO2011030334A1 (en) | 2009-09-09 | 2011-03-17 | New York University | Compositions and methods for treatment, diagnosis and prognosis of mesothelioma |
EP2496714B1 (en) * | 2009-11-04 | 2016-08-31 | DiamiR, LLC | Methods of using micro-rna from bodily fluids for diagnosis and monitoring of mild cognitive impairment |
EP2513310B1 (en) | 2009-12-16 | 2017-11-01 | CuRNA, Inc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
CA2785177C (en) | 2009-12-29 | 2019-09-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
CN102906264B (zh) | 2010-01-04 | 2017-08-04 | 库尔纳公司 | 通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病 |
WO2011088309A1 (en) | 2010-01-14 | 2011-07-21 | Regulus Therapeutics Inc. | Microrna compositions and methods |
US8946182B2 (en) | 2010-01-25 | 2015-02-03 | Curna, Inc. | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 |
KR101838308B1 (ko) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | 피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료 |
WO2011108930A1 (en) * | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
WO2011116152A2 (en) | 2010-03-16 | 2011-09-22 | Sanford -Burnham Medical Research Institute | Delivery of agents using interfering nanoparticles |
CA2795281A1 (en) | 2010-04-09 | 2011-10-13 | Curna, Inc. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
US20130131148A1 (en) | 2010-04-12 | 2013-05-23 | Noam Shomron | Micro-rna for cancer diagnosis, prognosis and therapy |
TWI586356B (zh) | 2010-05-14 | 2017-06-11 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
AR081209A1 (es) | 2010-05-19 | 2012-07-04 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11 |
NO2576783T3 (ja) | 2010-05-26 | 2018-04-28 | ||
WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
WO2012009347A2 (en) | 2010-07-12 | 2012-01-19 | Opko Curna Llc | Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3 |
CN103180461A (zh) | 2010-07-25 | 2013-06-26 | 纽约大学 | 用于间皮瘤预后的组合物和方法 |
EP2598657B1 (en) | 2010-08-01 | 2016-10-05 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Microrna patterns for the diagnosis, prognosis and treatment of melanoma |
EP2625274B1 (en) | 2010-10-06 | 2017-07-19 | CuRNA, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
KR101343616B1 (ko) | 2010-10-08 | 2013-12-20 | 연세대학교 산학협력단 | 췌장암 치료용 약제학적 조성물 및 췌장암 치료제 스크리닝 방법 |
JP6336755B2 (ja) | 2010-11-12 | 2018-06-06 | ザ ジェネラル ホスピタル コーポレイション | ポリコームに関連する非コードrna |
US20140045924A1 (en) | 2010-12-15 | 2014-02-13 | Medimmune, Llc | Melanoma treatments |
AU2011352036A1 (en) * | 2010-12-31 | 2013-07-18 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
US8883757B2 (en) | 2011-01-03 | 2014-11-11 | Rosetta Genomics Ltd. | Compositions and methods for treatment of ovarian cancer |
EP2474617A1 (en) * | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
AU2012212105A1 (en) * | 2011-02-03 | 2013-09-12 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-124 |
US9132152B2 (en) | 2011-02-10 | 2015-09-15 | The Regents Of The University Of California | Compositions and methods for generating induced pluripotent stem cells |
CA2830301A1 (en) | 2011-03-18 | 2012-09-27 | Baylor Research Institute | Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis |
US8987224B2 (en) * | 2011-08-05 | 2015-03-24 | Baylor College Of Medicine | MicroRNA-198 as a tumor suppressor in pancreatic cancer |
WO2013056216A1 (en) * | 2011-10-14 | 2013-04-18 | New York University | Micrornas and methods of using same |
CN104080461A (zh) | 2011-11-30 | 2014-10-01 | 雪松-西奈医学中心 | 靶向微小rna mir-409-5p、mir-379和mir-154*来治疗前列腺癌骨转移和耐药性肺癌 |
US9745578B2 (en) | 2011-11-30 | 2017-08-29 | Cedars-Sinai Medical Center | Targeting microRNA miR-409-3P to treat prostate cancer |
US20140363469A1 (en) * | 2012-01-19 | 2014-12-11 | Alnylam Pharmaceuticals, Inc. | Viral attenuation and vaccine production |
HUE040179T2 (hu) | 2012-03-15 | 2019-02-28 | Curna Inc | Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén |
EP2838541A1 (en) * | 2012-04-20 | 2015-02-25 | Agency For Science, Technology And Research | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies |
US10059941B2 (en) | 2012-05-16 | 2018-08-28 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
SG11201407486PA (en) | 2012-05-16 | 2014-12-30 | Rana Therapeutics Inc | Compositions and methods for modulating utrn expression |
AU2013262699A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating ATP2A2 expression |
EA201492119A1 (ru) | 2012-05-16 | 2015-05-29 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии apoa1 и abca1 |
CN104602714A (zh) | 2012-05-16 | 2015-05-06 | Rana医疗有限公司 | 用于调节bdnf表达的组合物和方法 |
EP2850188A4 (en) | 2012-05-16 | 2016-01-20 | Rana Therapeutics Inc | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE MULTIGENIC FAMILY OF HEMOGLOBIN |
EP3511416A1 (en) | 2012-05-16 | 2019-07-17 | Translate Bio MA, Inc. | Compositions and methods for modulating gene expression |
US20150159161A1 (en) | 2012-05-16 | 2015-06-11 | Rana Therapeutics, Inc. | Compositions and methods for modulating pten expression |
CN104583402A (zh) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节mecp2表达的组合物和方法 |
WO2014011975A2 (en) | 2012-07-12 | 2014-01-16 | Baylor College Of Medicine | Micrornas sensitize cancers to therapy |
US9096853B2 (en) * | 2012-09-24 | 2015-08-04 | U.S. Department Of Veterans Affairs | Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity |
ES2782825T3 (es) | 2012-10-31 | 2020-09-16 | Univ Rockefeller | Tratamiento de cáncer de colon metastásico |
US10201556B2 (en) | 2012-11-06 | 2019-02-12 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway |
US10697020B2 (en) * | 2013-05-15 | 2020-06-30 | The Research Foundation For The State University Of New York | MicroRNA-129 as a biomarker for colorectal cancer |
EP3004354A4 (en) | 2013-06-07 | 2017-01-11 | Rana Therapeutics, Inc. | Compositions and methods for modulating foxp3 expression |
US20150151004A1 (en) * | 2013-06-14 | 2015-06-04 | The University Of Kansas | Methods and compositions of modulating tumor initiating cells and the use thereof |
AU2014342535B2 (en) * | 2013-10-28 | 2020-04-02 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating neuronal excitability and motor behavior |
US20160312301A1 (en) | 2013-12-20 | 2016-10-27 | The Feinstein Institute For Medical Research | Microrna biomarkers for ovarian cancer |
JP2017511694A (ja) | 2014-02-12 | 2017-04-27 | トーマス・ジェファーソン・ユニバーシティ | マイクロrna阻害剤を使用するための組成物および方法 |
KR101596166B1 (ko) | 2014-10-07 | 2016-02-19 | 가톨릭대학교 산학협력단 | 유방암 진단 및 치료를 위한 마이크로 rna의 용도 |
US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
EP3331546B1 (en) | 2015-08-03 | 2023-10-04 | Biokine Therapeutics Ltd. | Cxcr4 inhibitor for the treatment of cancer |
US10053696B2 (en) | 2016-01-21 | 2018-08-21 | University Of South Carolina | MiRNA-489 in treatment of breast cancer |
CA3042401A1 (en) | 2016-11-01 | 2018-05-11 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
US10443055B2 (en) | 2016-12-22 | 2019-10-15 | Beth Israel Deaconess Medical Center | Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer |
US10988766B2 (en) | 2017-01-06 | 2021-04-27 | Oregon Health & Science University | Compositions and methods used in diagnosing and treating colorectal cancer |
WO2018136919A2 (en) | 2017-01-23 | 2018-07-26 | Trustees Of Boston University | Methods relating to lung cancer |
KR101953300B1 (ko) | 2018-06-22 | 2019-02-28 | 의료법인 성광의료재단 | 탁산계 항암제 내성 암의 진단 및 치료를 위한 조성물, 키트 및 방법 |
MA53669A (fr) | 2018-09-20 | 2021-07-28 | Modernatx Inc | Compositions et procédés d'administration d'acides nucléiques |
AU2019381681A1 (en) | 2018-11-13 | 2021-05-27 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating miR-10b activity |
WO2020154207A1 (en) | 2019-01-22 | 2020-07-30 | Research Institute At Nationwide Children's Hospital | A novel method for monitoring and treating oral cancer |
US20220145304A1 (en) | 2019-03-14 | 2022-05-12 | The Research Foundation For The State University Of New York | Modified micrornas and their use in the treatment of cancer |
US20220275374A1 (en) | 2019-11-14 | 2022-09-01 | The Board Of Regents Of The University Of Oklahoma | Oligonucleotide interference treatments of prostate cancer |
US11965162B2 (en) | 2020-04-16 | 2024-04-23 | The Johns Hopkins University | MicroRNA and inhibitors thereof and methods of treatment |
WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
-
2017
- 2017-10-30 CA CA3042401A patent/CA3042401A1/en active Pending
- 2017-10-30 MX MX2019005101A patent/MX2019005101A/es unknown
- 2017-10-30 JP JP2019523008A patent/JP7130639B2/ja active Active
- 2017-10-30 EP EP17867742.3A patent/EP3534912A4/en active Pending
- 2017-10-30 AU AU2017353907A patent/AU2017353907B2/en active Active
- 2017-10-30 KR KR1020197015788A patent/KR102502248B1/ko active IP Right Grant
- 2017-10-30 BR BR112019008810A patent/BR112019008810A2/pt active Search and Examination
- 2017-10-30 CN CN201780081456.7A patent/CN110290794A/zh active Pending
- 2017-10-30 WO PCT/US2017/059011 patent/WO2018085198A1/en unknown
-
2018
- 2018-10-31 US US16/176,137 patent/US11584932B2/en active Active
-
2019
- 2019-10-30 CN CN201980087509.5A patent/CN113573781A/zh active Pending
- 2019-10-30 WO PCT/US2019/058706 patent/WO2020092466A1/en unknown
- 2019-10-30 SG SG11202104571RA patent/SG11202104571RA/en unknown
- 2019-10-30 KR KR1020217016590A patent/KR20210088614A/ko active Search and Examination
- 2019-10-30 AU AU2019371830A patent/AU2019371830A1/en active Pending
- 2019-10-30 EP EP19878184.1A patent/EP3873613A4/en active Pending
-
2021
- 2021-05-02 IL IL282836A patent/IL282836A/en unknown
-
2022
- 2022-08-24 JP JP2022133279A patent/JP2022173194A/ja active Pending
-
2023
- 2023-01-25 US US18/159,233 patent/US20230365972A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013166766A (ja) | 2005-09-12 | 2013-08-29 | Ohio State Univ Research Foundation | Bcl2関連癌の診断及び療法のための組成物及び方法 |
JP2010504349A (ja) | 2006-09-19 | 2010-02-12 | アシュラジェン インコーポレイテッド | 治療的介入の標的としてmiR−143によって調節される遺伝子および経路 |
JP2012532123A (ja) | 2009-06-29 | 2012-12-13 | アプタバイオ セラピュティックス インコーポレイテッド | 治療効能のある変形核酸及びグアノシンを含有するオリゴヌクレオチド変形体 |
US20130109628A1 (en) | 2010-07-15 | 2013-05-02 | Emory University | Microrna compositions and methods related thereto |
WO2014100252A1 (en) | 2012-12-18 | 2014-06-26 | University Of Washington Through Its Center For Commercialization | Methods and compositions to modulate rna processing |
Non-Patent Citations (2)
Title |
---|
Gene,2013年,532,pp.87-93 |
Oncotarget,2015年,6(35),pp. 38139-38150 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
IL282836A (en) | 2021-06-30 |
KR102502248B1 (ko) | 2023-02-21 |
WO2018085198A1 (en) | 2018-05-11 |
US20230365972A1 (en) | 2023-11-16 |
US11584932B2 (en) | 2023-02-21 |
US20190062754A1 (en) | 2019-02-28 |
EP3534912A1 (en) | 2019-09-11 |
AU2017353907A1 (en) | 2019-05-23 |
EP3534912A4 (en) | 2020-10-07 |
JP2019533697A (ja) | 2019-11-21 |
KR20190086688A (ko) | 2019-07-23 |
CN110290794A (zh) | 2019-09-27 |
SG11202104571RA (en) | 2021-06-29 |
JP2022173194A (ja) | 2022-11-18 |
CN113573781A (zh) | 2021-10-29 |
AU2017353907B2 (en) | 2023-11-30 |
CA3042401A1 (en) | 2018-05-11 |
WO2020092466A1 (en) | 2020-05-07 |
KR20210088614A (ko) | 2021-07-14 |
EP3873613A1 (en) | 2021-09-08 |
EP3873613A4 (en) | 2023-11-15 |
AU2019371830A1 (en) | 2021-06-03 |
BR112019008810A2 (pt) | 2019-07-16 |
MX2019005101A (es) | 2019-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7130639B2 (ja) | 5-ハロウラシル修飾マイクロrna及びがんの処置におけるその使用 | |
AU2017232496B2 (en) | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder | |
US20220145304A1 (en) | Modified micrornas and their use in the treatment of cancer | |
JP2021513508A (ja) | 抗がんマイクロrna及びその脂質製剤 | |
JPWO2005095613A1 (ja) | Rad51の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用 | |
US11236337B2 (en) | 5-halouracil-modified microRNAs and their use in the treatment of cancer | |
TWI526211B (zh) | RNAi molecules for thymidine nucleotide synthesis enzymes and their use | |
US20220090076A1 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
US10697020B2 (en) | MicroRNA-129 as a biomarker for colorectal cancer | |
US20230151363A1 (en) | Modified short-interfering rna compositions and their use in the treatment of cancer | |
WO2017160797A1 (en) | Combination therapy with c-myc nucleic acid inhibitors and selective cdk7 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210726 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210728 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220707 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220725 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220824 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7130639 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |